1. Generics Bulletin

Dr Reddy’s Sees Tocilizumab Clear Phase I

Indian Firm’s Biosimilar Rival To Actemra/RoActemra Moves Into Phase III Trials

 
• By Dave Wallace

Dr Reddy’s says it is moving its biosimilar tocilizumab candidate into Phase III trials after successfully completing a Phase I study for the proposed rival to Actemra/RoActemra.

Dr Reddy's Magnifying Glass
Dr Reddy’s has successfully completed a Phase I study for tocilizumab • Source: Shutterstock

Dr Reddy’s says its “DRL TC” proposed biosimilar version of Actemra/RoActemra (tocilizumab) has achieved a milestone after successfully completing a Phase I study that demonstrated pharmacokinetic equivalence and similarity in pharmacodynamic parameters, safety and immunogenicity with both EU- and US-sourced reference products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products